Back
 JTR  Vol.6 No.3 , September 2018
Pre-Extensively Drug Resistant Tuberculosis (Pre-XDR-TB) among Pulmonary Multidrug Resistant Tuberculosis (MDR-TB) Patients in Bangladesh
Abstract: Background & Objectives: Emergence of drug resistant Tuberculosis (TB) is a major obstacle in the TB control programme of Bangladesh. This study was carried out to detect pre-extensively drug resistant TB (pre-XDR-TB) cases among the multidrug resistant TB (MDR-TB) patients in Bangladesh, as the early detection of pre-XDR-TB can guide clinicians in the appropriate modification of MDR-TB treatment regimen with effective drugs to prevent treatment failure. Methodology: A total of 68 MDR-TB cases were enrolled in this study. Multiplex Real-time PCR was done to detect pre-XDR-TB cases directly from sputum samples of MDR-TB patients. Results: Out of 68 MDR-TB cases 11 (16.18%) cases were detected as pre-XDR-TB. The resistant profile of the 11 pre-XDR-TB revealed 9 (81.82%) cases of fluoroquinolone (FLQ) resistant pre-XDR-TB and 2 (18.18%) cases of injectable second line (ISL) agent resistant pre-XDR-TB. Out of 11 pre-XDR-TB cases 7 (63.64%) cases had history of taking treatment for MDR-TB regularly, 1 (9.09%) case had history of taking treatment for MDR-TB irregularly and 3 (27.27%) cases had no history of taking treatment for MDR-TB. Conclusion: This study encountered a high rate of pre-XDR-TB cases along with a significant number of primarily resistant bacilli which is of concern in the management of MDR-TB. It is evident that Bangladesh is in urgent need to device strategies for rapid and early detection of pre-XDR-TB in order to prevent treatment failure of MDR-TB cases and also to halt the progression of MDR-TB cases to extensively drug resistant TB (XDR-TB), which is not only difficult but also very expensive to treat.
Cite this paper: Tasnim, T. , Tarafder, S. , Alam, F. , Sattar, H. and Mostofa Kamal, S. (2018) Pre-Extensively Drug Resistant Tuberculosis (Pre-XDR-TB) among Pulmonary Multidrug Resistant Tuberculosis (MDR-TB) Patients in Bangladesh. Journal of Tuberculosis Research, 6, 199-206. doi: 10.4236/jtr.2018.63018.
References

[1]   NTP (2016) Annual Tuberculosis Report 2016. National Tuberculosis Control Program (NTP), Dhaka, 3.
http://www.ntp.gov.bd/ntp_dashboard/magazines_image/1487245939.pdf

[2]   Banerjee, R., Allen, J., Westenhouse, J., Oh, P., Elms, W., Desmond, E., Nitta, A., Royce, S. and Flood, J. (2008) Extensively Drug-Resistant Tuberculosis in California, 1993-2006. Clinical Infectious Diseases, 47, 450-457.
https://doi.org/10.1086/590009

[3]   Adwani, S., Desani, D.U. and Joshi, M.J. (2016) Prevalence of Pre-Extensively Drug-Resistant Tuberculosis (Pre XDR-TB) and Extensively Drug-Resistant Tuberculosis (XDR-TB) among Pulmonary Multidrug Resistant Tuberculosis (MDR-TB) at a Tertiary Care Center in Mumbai. Journal of Krishna Institute of Medical Sciences University, 5, 13-19.

[4]   WHO (2016) Global Tuberculosis Report 2016, 5-49.
http://www.who.int/tb/publications/global_report/en/

[5]   Mannan, M.A.U., Mushtaq, A. and Naqvi, S. (2017) Prevalence of Pre-XDR-TB, XDR-TB among MDR-TB Patients Registered at PMDT Site Nishtar Hospital Multan Pakistan. European Respiratory Journal, 50, PA2764.

[6]   Rao, N., Baig, S., Hussain, N., Ahmed, N. and Rao, D. (2015) Prevalence of pre-XDR-TB, XDR-TB among MDR-TB Patients Registered at Ojha Institute of Chest Diseases, Karachi. European Respiratory Journal, 46, PA2715.
https://doi.org/10.1183/13993003.congress-2015.PA2715

[7]   STAC (2016) Statistics & Information of MDR and XDR TB in SAARC Region. STAC, Nepal, 23.

[8]   WHO (2007) Policy Guidance on TB Drug Susceptibility Testing (DST) of Second Line Drugs (SLD). WHO Press, Geneva, Switzerland.
http://apps.who.int/iris/bitstream/handle/10665/70500/WHO_HTM_TB_2008.392_eng.pdf?sequence=1

[9]   Porwal, C., Kaushik, A., Makkar, N., Banavaliker, J.N., Hanif, M. and Singla, R. (2013) Incidences and Risk Factors for Extensively Drug Resistant Tuberculosis in Delhi Region. PLoS One, 8, e55299.
https://doi.org/10.1371/journal.pone.0055299

[10]   Hu, Y., Hoffner, S., Wu, L., Zhao, Q., Jiang, W. and Xua, B. (2013) Prevalence and Genetic Characterization of Second-Line Drug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in Rural China. Antimicrobial Agents and Chemotherapy, 57, 3857-3863.
https://doi.org/10.1128/AAC.00102-13

[11]   Yuan, X., Zhang, T., Kawakami, K., Zhu, J., Li, H., Lei, J. and Tu, S. (2012) Molecular Characterization of Multidrug- and Extensively Drug-Resistant Mycobacterium Tuberculosis Strains in Jiangxi, China. Journal of Clinical Microbiology, 50, 2404-2413.
https://doi.org/10.1128/JCM.06860-11

[12]   Singhal, P., Dixit, P., Singh, P., Jaiswal, I., Sinhg, M. and Jain, A. (2016) A Study on Pre-XDR & XDR Tuberculosis & Their Prevalent Genotypes in Clinical Isolates of Mycobacterium Tuberculosis in North India. The Indian Journal of Medical Research, 145, 341-347.
http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2016;volume=143;issue=3;spage=341;epage=347;aulast=Singhal

[13]   Daniel, O., Osman, E., Oladimeji, O. and Dairo, O.G. (2013) Pre-Extensive Drug Resistant Tuberculosis (Pre-XDR-TB) among MDR-TB Patents in Nigeria. Global Advanced Research Journal of Microbiology, 2, 22-25.

 
 
Top